2. Amyotrophic lateral sclerosis
508 clinical trials,   530 drugs   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-001688-49-GB
(EUCTR)
14/08/200628/04/2006A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a.A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a. Early stage of amyotrophic lateral sclerosis (ALS)
MedDRA version: 8.1;Level: PT;Classification code 10002026
TEVA Pharmaceutical Industries. Ltd.NULLNot Recruiting Female: yes
Male: yes
366Phase 2Belgium;Germany;Italy;United Kingdom
2NCT00326625
(ClinicalTrials.gov)
July 31, 200616/5/2006Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate Injection in Subjects With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: 40 mg glatiramer acetate;Drug: PlaceboTeva Pharmaceutical Industries, Ltd.NULLCompleted18 Years70 YearsAll366Phase 2Belgium;France;Germany;Israel;Italy;United Kingdom
3EUCTR2006-001688-49-DE
(EUCTR)
31/07/200624/05/2006A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a.A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a. Early stage of amyotrophic lateral sclerosis (ALS)
MedDRA version: 8.1;Level: PT;Classification code 10002026
Product Name: 40 mg glatiramer acetate
Product Code: 40 mg GA
TEVA Pharmaceutical Industries. Ltd.NULLNot RecruitingFemale: yes
Male: yes
300United Kingdom;Germany;Belgium;Italy
4EUCTR2006-001688-49-BE
(EUCTR)
26/06/200610/05/2006A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a.A multi-national, multi-centre, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, tolerability and safety of 40 mg glatiramer acetate injection in subjects with amyotrophic lateral sclerosis (ALS) - n.a. Early stage of amyotrophic lateral sclerosis (ALS)
MedDRA version: 8.1;Level: PT;Classification code 10002026
Product Name: 40 mg glatiramer acetate
Product Code: 40 mg GA
TEVA Pharmaceutical Industries. Ltd.NULLNot RecruitingFemale: yes
Male: yes
300Germany;United Kingdom;Belgium;Italy